Following the seminal discovery of the JAK2 mutation and the role of dysregulated JAK-STAT signaling in MPN, there have been many efforts to improve the treatment of patients with MPN, in particular MF [11, 54]. Here, JAK2 is linked to myeloproliferative neoplasm.